Research output: Contribution to journal › Article › peer-review
Exosomal miRNA-146a is downregulated in clear cell renal cell carcinoma patients with severe immune-related adverse events. / Иванова, Елизавета Алексеевна; Асадуллина, Дилара Динаровна; Рахимов, Радмир Радимович; Измайлов, Адель Альбертович; Гилязова, Гульшат Руслановна; Измайлов, Альберт Аделевич; Галимов, Шамиль Нуриманович; Павлов, Валентин Николаевич; Хуснутдинова, Эльза Камилевна; Гилязова, Ирина Ришатовна.
In: Non-coding RNA Research, Vol. 7, No. 3, 09.2022, p. 159-163.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Exosomal miRNA-146a is downregulated in clear cell renal cell carcinoma patients with severe immune-related adverse events
AU - Иванова, Елизавета Алексеевна
AU - Асадуллина, Дилара Динаровна
AU - Рахимов, Радмир Радимович
AU - Измайлов, Адель Альбертович
AU - Гилязова, Гульшат Руслановна
AU - Измайлов, Альберт Аделевич
AU - Галимов, Шамиль Нуриманович
AU - Павлов, Валентин Николаевич
AU - Хуснутдинова, Эльза Камилевна
AU - Гилязова, Ирина Ришатовна
N1 - Publisher Copyright: © 2022 The Authors
PY - 2022/9
Y1 - 2022/9
N2 - Here we report the results of the pilot project of exosomal miRNA expression levels in clear cell renal cell carcinoma (ccRCC) patients with different clinical response to ICIs (nivolumab) and treatment related toxicity. Immune-related adverse events (irAEs) are a major cause of immune checkpoint inhibitors cancellation and therapy failure. Modern studies demonstrate evidence that exosomes are of great importance in the formation of tumor resistance to ICIs drugs and therapy. We performed exosomal miRNA-146a expression analysis using qPCR on 86 ccRCC patients and revealed a statistically significant (p = 0.01) decreased expression level in ccRCC patients with CTCAE grade 3–4 (M±SEM 1.71 ± 0.13) compared to CTCAE grade 0–2 group (M±SEM 2.30 ± 0.24). The expression levels of miRNA-126, miRNA-218 and miRNA-410 did not show statistically significant differences in the comparison groups (p > 0.05). Association analysis of rs2910164 in the miRNA-146a gene demonstrated that CC genotype and C allele carriers had higher risk of developing severe irAEs (p = 0.03, OR = 6.12; p = 0.01, OR = 2.42, respectively) compare with GG and GC carriers. That is the first attempt to identify biomarkers of ICIs treatment efficacy for ccRCC in the Volga-Ural region based on exosomal miRNAs analysis.
AB - Here we report the results of the pilot project of exosomal miRNA expression levels in clear cell renal cell carcinoma (ccRCC) patients with different clinical response to ICIs (nivolumab) and treatment related toxicity. Immune-related adverse events (irAEs) are a major cause of immune checkpoint inhibitors cancellation and therapy failure. Modern studies demonstrate evidence that exosomes are of great importance in the formation of tumor resistance to ICIs drugs and therapy. We performed exosomal miRNA-146a expression analysis using qPCR on 86 ccRCC patients and revealed a statistically significant (p = 0.01) decreased expression level in ccRCC patients with CTCAE grade 3–4 (M±SEM 1.71 ± 0.13) compared to CTCAE grade 0–2 group (M±SEM 2.30 ± 0.24). The expression levels of miRNA-126, miRNA-218 and miRNA-410 did not show statistically significant differences in the comparison groups (p > 0.05). Association analysis of rs2910164 in the miRNA-146a gene demonstrated that CC genotype and C allele carriers had higher risk of developing severe irAEs (p = 0.03, OR = 6.12; p = 0.01, OR = 2.42, respectively) compare with GG and GC carriers. That is the first attempt to identify biomarkers of ICIs treatment efficacy for ccRCC in the Volga-Ural region based on exosomal miRNAs analysis.
KW - Exosomal miRNAs
KW - Gene expression
KW - Gene polymorphism
KW - Immune-related adverse events
KW - Nivolumab
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85133520611&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/f73022ec-0aa3-3425-b9df-2dafe0750702/
U2 - 10.1016/j.ncrna.2022.06.004
DO - 10.1016/j.ncrna.2022.06.004
M3 - Article
C2 - 35846077
VL - 7
SP - 159
EP - 163
JO - Non-coding RNA Research
JF - Non-coding RNA Research
SN - 2468-0540
IS - 3
ER -
ID: 100664490